Key result
The 2026 ESC heart failure guidelines introduce a three-tiered framework for medical therapy and reclassify mildly reduced ejection fraction into the reduced ejection fraction category.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The mildly reduced LVEF phenotype was introduced in previous guidelines to focus on patients not usually included in clinical trials. However, we know that these patients share similar pathophysiology and benefit from similar treatments as those with reduced LVEF. Thus, we decided to simplify the classification.”
“The term 'guideline-directed medical therapy (GDMT)' was introduced more than 10 years ago. However, there have been further advances since then, creating some uncertainty as to what GDMT actually means today.”
“The European Society of Cardiology's updated guidelines send a clear message: in heart failure, waiting is not a neutral choice. The evidence from trials such as MOMENTUM 3, GUIDE-HF and MONITOR-HF clinical trials have consistently shown that earlier intervention changes outcomes, whether through remote monitoring with Abbott's CardioMEMS HF System, or mechanical support with the HeartMate 3 LVAD. Today's enhanced guidelines give physicians the backing to act on that evidence with confidence to help save lives and avoid heart failure hospitalizations.”
The 2026 ESC heart failure guidelines introduce a simplified classification and a three-tiered therapy framework to accelerate the implementation of effective treatments and emphasize early prevention.
The 2026 European Society of Cardiology (ESC) guidelines for the management of heart failure introduce a series of important changes intended to simplify classification, accelerate implementation of effective therapies, and shift care toward earlier prevention and intervention. Among the most notable changes are the incorporation of patients with mildly reduced left ventricular ejection fraction into the heart failure with reduced ejection fraction category, the replacement of the traditional concept of guideline-directed medical therapy with a three-tiered framework of foundational medical therapy, additional medical therapy, and guideline-directed interventional therapy, and greater emphasis on prevention through the formal use of stages A to D. The guidelines also favor the term “decompensated heart failure” over “acute heart failure,” reinforcing the concept that clinical deterioration often reflects an evolving process rather than an abrupt event. These changes provide a clearer and more actionable clinical pathway and emphasize rapid initiation of foundational therapies and timely referral for advanced heart failure care. At the same time, simplification may reduce phenotypic granularity, and some recommendations warrant continued discussion regarding the relationship between recommendation strength and supporting evidence. The Class I recommendation for mineralocorticoid receptor antagonists in symptomatic heart failure with preserved ejection fraction illustrates this tension, particularly given differences between steroidal and non-steroidal agents and across patient phenotypes. Overall, the 2026 ESC guidelines provide a pragmatic, forward-looking framework that may improve implementation and continuity of heart failure care. Their greatest impact, however, will depend not only on scientific rigor, but also on thoughtful interpretation, individualized application, and timely translation into everyday clinical practice.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) conducted a review in Heart failure. 2026 ESC heart failure guidelines was evaluated. The 2026 ESC heart failure guidelines introduce a three-tiered framework for medical therapy and reclassify mildly reduced ejection fraction into the reduced ejection fraction category.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: